In the news:
Gilead Agrees to Allow Generic Version of Groundbreaking H.I.V. Shot in Poor Countries - Here are Monday's biggest analyst calls: Nvidia, Apple, Amazon, Netflix, Campbell Soup, Gilead, American Express & more - Gilead's tie up with generic cos may not address HIV challenge - Gilead's tie up with generic cos may not address HIV challenge - Ferozsons partners with Gilead for HIV drugs - Dr Reddy's, Hetero ink royalty-free pact with Gilead - Dr Reddy's, Hetero ink royalty-free voluntary licencing pacts with Gilead Sciences for HIV drug Lenacapavir - Gilead says its twice-yearly shot cut HIV infections by 96% in trial - Gilead Sciences alleges dangerous drug-counterfeiting operation at two NYC pharmacies in lawsuit - Activists Challenge Pharma Company Gilead Over HIV Medication
Gilead Sciences
Save
ShareKey facts
- city: Foster City
- state: CA
- country: United States
- sector: Health Care
- foundation year: 1987
- industry: Pharmaceuticals
- CEO: Daniel P. O'Day
Classified as: organization
Summary
Gilead Sciences is a company. It is located in Foster City, the United States and was founded in 1987. The company is part of the Health Care sector, specifically in the Pharmaceuticals industry.
Business see more
Gilead Sciences is one of the companies in the United States, companies in Pharmaceuticals, companies in Health Care and 3,466,499 companies in our database.
- Assets: 68B $
- Debt: 26.2B $
- Employees: 14,400 people
- Free cash flow: 8.7B $
- Market cap: 80.3B $
- Profits: 6.2B $
- Revenues: 27.5B $
Stocks from Gilead Sciences
Talking Points:
- Gilead Sciences, Inc.
- Gilead Sciences, Inc. is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines.
- The impossible is not impossible. It’s simply what hasn’t been achieved yet. Twitter guidelines: https://t.co/vWkdtfUf7N
- Our ~12,000 employees band together through science, grit, compassion and courage to prove the impossible wrong. At Gilead, the tangible results of your contributions are evident. Where every individual matters. Where all employees can enhance their skills through ongoing development.
- Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
Learn more about talking points